Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This kind of exposure is overdue and proving of the product. If they got what we think they got then our little stock will sail. If it doesn't impress the scientific world then it's not what I think it is and I'll make a decision to invest in other opportunities.
The fact that they are ready to show this to the experts has got me pretty excited.
This SHOULD be the turning point. Let's hope so.
eGene Inc. Will Exhibit at the 2006 Annual Meeting of the American Association for Clinical Chemistry in Chicago, Illinois, July 25-27, 2006
IRVINE, Calif., Jul 10, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developer of a revolutionary high-performance genetic analysis technology, today announced that it will exhibit at the 2006 Annual Meeting of the American Association for Clinical Chemistry (AACC) at the McCormick Place Convention Center in Chicago, Illinois, July 25-27, 2006.
AACC is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and other clinical laboratory science-related disciplines.
Ming S. Liu, CEO of eGene, made the announcement noting: "eGene will attend this meeting to introduce our technology to clinical society. We believe our portable HDA-GT12(TM) genetic analyzer has potential for many important uses in research/clinical laboratories including pathogens detection, cancer genetics research/screening, health-related genotyping application, etc. We will host a press conference and live system demonstrations during this meeting, so people can experience our technology that enables DNA analysis to take place in as little as minutes. eGene represents a paradigm shift in the way that scientists think about genetic analysis. Our automatic, affordable, user-friendly genotyping system represents the future of DNA analysis."
eGene's Booth Number is 2820.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
eGene Issued Chinese Patent for DNA Analyzer Technology; Protection in China for 20 Years
IRVINE, Calif., Jul 05, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developer of a revolutionary high-performance genetic analysis technology, announced today that the company was awarded Chinese Patent No. ZL 02 8 05 754.6. Issued on May 24, the 20-year Chinese patent protection is for "Optical Detection in a Multi-Channel Bio-Separation System." It marks the company's eighth patent worldwide for its technology that enables DNA analysis to take place in as little as minutes.
Ming S. Liu, CEO of eGene, noted: "This patent is important because we believe the Chinese market will prove to be very lucrative for eGene. Our portable HDA-GT12(TM) analyzer has the potential for many important uses in China, which needs a high-performance and low-cost system for genetically related analysis. This includes quickly identifying viral and bacterial DNA signatures, which assists in controlling the transmission of infectious diseases. Furthermore, our system is very useful in personal genotyping for medical-related testing and assisting in the development of 'designer drugs,' where a patient's DNA is compared to that of the specific drug to determine if the drug will be effective on that individual or if side effects may occur."
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
eGene and Daiichi Pure Chemicals Co., Ltd. Enter into Three Year Distribution Relationship in Japan
IRVINE, Calif., Jun 27, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that it has entered into a three year distribution agreement with Daiichi Pure Chemicals Co., Ltd., to promote and sell eGene's HDA-GT12 system in Japan.
Dr. Ming S. Liu, CEO of eGene, noted: "We are very pleased to work with Daiichi Pure Chemicals Co., Ltd. Both of us have seen the wonderful business opportunities for our genetic analyzer's use in the area Daiichi serves, and eGene believes that Daiichi's expertise will suit our product very well."
Daiichi Pure Chemicals Co., Ltd. is a subsidiary of Daiichi Sankyo Co., Ltd., the second largest pharmaceutical company in Japan.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures the quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
Very few OS and very few people know about it. This is good as there will be a rather large price jump as they get more revenue. So far so good.
eGene's HDA-GT12 Genetic Analyzer Demonstrates Its Revolutionary Technology for Gene Expression Market; Application Note Shows the Analyzer Provides the Automated High Throughput RNA Quality Control Analysis
IRVINE, Calif., May 31, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that its analyzer has demonstrated automated high-throughput RNA quality control analysis for the gene expression market. The application note is published in the May issue of BIOSCIENCE TECHNOLOGY.
BIOSCIENCE TECHNOLOGY is the recognized leader in delivering product news, application stories and feature stories on research techniques to those on the forefront of life science research. Each issue reaches more than 60,000 research scientists and directors, lab directors and managers, and principal investigators working in pharma, biotech, university and government labs. The article can be found at: http://www.bioprodmag.com/ShowPR~PUBCODE~090~ACCT~9000019603~ISSUE~060 5~RELTYPE~PAA~PRODCODE~00002739~PRODLETT~A.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.).
Dr. Ming S. Liu, acting CEO of eGene, noted: "Gene expression has become a mainstream technique in biology, medicine and drug development. Our HDA-GT12 platform is a revolutionary technology for RNA quality control checking. A researcher can check RNA quality for 12 samples in 10 minutes and 96 samples in less than 90 minutes.
"Our compact, automated high throughput digital HDA-GT12 genetic analyzer can play a major role in the gene expression market," he continued. "We can see increased demand in the current market, and more customers are integrating our HDA-GT12 system in their gene expression research."
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes the genetic fingerprints of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
or
Andrew Ponzo, 312-943-1100, ext. 17
aponzo@janispr.com
Copyright Business Wire 2006
eGene Adds Sales Director to Staff to Move Sales to Next Level
IRVINE, Calif., May 24, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading bioengineering company that has developed a compact and automated digital genetic analyzer, today announced that David Molnar has joined eGene as director of sales.
Molnar brings an extensive background in general sales management in the U.S. and Asia to the company. In his previous positions he has been responsible for adding $10 million to bottom-line profits in one year; leading growth of North American sales from $20 to $40 million in a three-year period and has negotiated multi-product, long-term agreements with major corporations.
"We are very excited to add David to our team," said Dr. Ming Liu, acting CEO of eGene Inc. "David brings a proven ability to generate significant sales, which is something that we have made a priority for 2006. I believe that his efforts will help increase eGene's visibility and revenues in the future."
Prior to joining eGene, Molnar was national sales manager of Matsuo Electronic of America Inc. (subsidiary of Matsuo Electric Co. Ltd., Japan) where he was responsible for revamping pricing structures to turnaround sales from 0% profit to a 15% profit in an industry where the average was 5-6%. Before that he was senior sales representative at Fisher Scientific Co. (previously Curtin Matheson) where he achieved top-10 sales ranking out of 300 sales reps, receiving numerous supplier and company awards for excellent performance. Prior to that affiliation he was sales manager at LabMart where he drove sales from 0 to $10 million, surpassing sales goals by 30%. His first position was as a sales representative at Curtin Matheson Sci. Co., where he was responsible for sales of high-technology equipment and chemicals to biotech, clinical lab, hospital and research facilities. He spearheaded the development of a non-producing territory to the No. 1 producer in the branch, consistently surpassing sales goals by 10-20% during the 11 years he was with the company.
He holds a Bachelor of Science degree from Findlay College in Findlay, Ohio.
eGene ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
The company has developed the HDA-GT12 (high-performance DNA analyzer for genotyping on 12 channels) which is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
Great results and we are down, terrible market right now. Very difficult to hold any gains, irregardless of results.
eGene Revenue Increases 85 Percent in First Quarter 2006 Compared to First Quarter 2005
IRVINE, Calif., May 15, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading bioengineering company that has developed a compact and automated digital genetic analyzer, today announced its results for the first quarter ending March 31, 2006.
For the quarter, the company increased its revenue 85 percent from one year ago, recording sales of $507,211 versus first quarter sales of $274,151 in 2005. Gross profit margin increased to 64 percent in the first quarter of 2006, from 51 percent in the first quarter of 2005. The company recorded a net loss of $164,471 or ($0.01) per share compared to a net loss a year ago of $266,366 or ($0.02) per share. The 2006 net loss per share is based on weighted average shares outstanding of 18,117,517, while the 2005 net loss per share reflected weighted average shares outstanding of 14,787,659.
The company attributed the increase in revenue to its continuous product sale ramp up and distribution efforts as it sells its units worldwide to academic, hospital and commercial laboratories.
In the quarter, the company used its resources for research and development applications of its HDA system platform, especially considering the current urgent need in the biological detection market. Detection of the influenza A virus (known as the avian or "bird" flu virus) is a major focus at the present time for the company. As an acute respiratory infection, rapid detection of the influenza A virus is important and the company has announced that its HDA-GT12(TM) Genetic Analyzer is capable of detecting this virus in as little as six minutes or at a sample analysis rate of two samples per minute.
In addition to its own product development research, the company noted that many of the users of its system have started to publish results in peer-reviewed scientific journals that are providing third-party endorsements of the advantages of using the eGene HDA system in genetically related research work.
eGene noted that total expenses for the quarter were $490,900 which was $84,142 higher than those incurred one year earlier. The major expense increases were $78,000 for non-cash expenses associated with stock option expenses and warrants issued for services. The company anticipates that selling and marketing expenses are expected to increase as it carries out its planned amplified sales effort.
eGene has developed the HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels) which is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may very from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
eGene Profiled in Prestigious 'Genetic Engineering News' Magazine
IRVINE, Calif., May 12, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading biotechnology company that has developed a compact and automated digital genetic analyzer, is the focus of a corporate profile in the prestigious "Genetic Engineering News" magazine's May 15 issue.
"Genetic Engineering News" is the most widely read biotechnology publication around the globe, read by biotechnology executives and investors worldwide. The article can be found at: http://www.genengnews.com/current/article.aspx?id=1620.
In the May 15 issue, writer Carol Potera describes eGene as a company that "transforms the genetic analysis field." The story states: "Just as email and eBay changed the way people think about communications and retailing, the name eGene represents a paradigm shift in the way that scientists think about genetic analysis." The story notes that Dr. Ming Liu, acting CEO of eGene, notes that "the automatic, affordable, user-friendly capillary electrophoresis genotyping system, offered by eGene, represents the future of DNA analysis."
The HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels) is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage. eGene recently announced that it can successfully identify the DNA of the bird flu virus through RT-PCR method in as little as six minutes for 12 samples or 50 minutes for 96 samples.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Co. Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
The Bellwether Report Begins Due-Diligence on eGene Inc
May 05, 2006 (M2 PRESSWIRE via COMTEX) -- eGene Inc (OTCBB: EGEI), is a company that our research team will be tracking over the ensuing weeks. They recently came out with a significant corporate development, causing a market stir. The BWR Research Team will continue to bring its subscribers cutting edge research tools, and second to none customer service.
eGene Inc focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing, yesterday afternoon they announce its HDA-GT12 Genetic Analyzer shows compatibility of detecting the influenza A virus, commonly known as the avian flu virus.
The automatic analysis process is less than six minutes. The company has demonstrated that its system platform can handle 12 RT-PCR amplified virus samples in six minutes, or at a sample analysis rate of two samples per minute.
The virus naturally infects humans and other mammalian species such as swine, horse and avian species," said Dr. Ming Liu, acting CEO of the company. "The concerns of a human outbreak of the avian influenza virus have raised significant concerns. Our system can rapidly detect whether we are dealing with an ordinary flu strain or the more serious avian strain. Furthermore, genetic analysis is one of the effective ways to determine whether the virus has mutated to a point where it is dangerous to humans. The need to perform this analysis rapidly cannot be understated in today's world where an airplane ride can transmit a virus thousands of miles in a short period of time."
"The virus naturally infects humans and other mammalian species such as swine, horse and avian species," said Dr. Ming Liu, acting CEO of the company. "The concerns of a human outbreak of the avian influenza virus have raised significant concerns. Our system can rapidly detect whether we are dealing with an ordinary flu strain or the more serious avian strain.
Furthermore, genetic analysis is one of the effective ways to determine whether the virus has mutated to a point where it is dangerous to humans. The need to perform this analysis rapidly cannot be understated in today's world where an airplane ride can transmit a virus thousands of miles in a short period of time."
The HDA-GT12 system uses a consumable multi-channel cartridge that can be used to detect multiple influenza samples simultaneously. The cartridge is engaged to eGene's system and can automatically inject and analyze 12 DNA samples at the same time for results available in six minutes, or for 96 samples from a PCR plate for results available in 50 minutes -- less than an hour.
"This automated and affordable system can be easily operated for avian influenza virus detection," said Dr. Liu.
He noted that eGene recently tested its system utilizing the reagents from In-Vitro Diagnostic FluAVision kits provided by DNA Technology A/S (Denmark). Positive control of influenza A from the testing kit was used for amplification and analyzed with the eGene HDA-GT12 system.
Previously, eGene explained that its analyzer, if placed in airports and other ports of entry throughout the world, can be used to determine if the flu virus is present in the DNA samples of travelers entering -- or leaving -- a given locale.
"The fact that our compact, low-cost, automated digital genetic analysis system platform can do the detection and analysis work in a short time means that should a flu pandemic break out, our system could easily detect and notify officials of a virus carrier who may not be exhibiting physical symptoms of the flu. This is very important, because with illnesses like the flu, the virus is already present and multiplying even in the absence of physical symptoms," explained Dr. Liu. "This could potentially stop the spread of the flu."
Following this announcement, eGene Inc, instantly took off as it trade from $.just below $0.80 to above$1.40 in the last half hour of trading on huge volume. Since then the company has corrected itself a bit as it currently trades at $0.99 on volume of 393,933 shares. I feel that this company could be a great trading opportunity ,especially on this bounce as the Bird Flu continues to spread with birds beginning to migrate for the summer months. The BWR Research Team will continue to follow the market sentiment on this company and numerous others.
To review research on large cap companies like eGene Inc, as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!!
The Bellwether Report will continue to research all of the markets to bring you exciting opportunities!! If you are interested in receiving more information on these small or large cap opportunities as well as other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.
Companies looking to advertise with Bellwether Report should email jlee@bellwetherreport.com with the subject line (Advertising).
All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.
Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web Inquiries to info@m2.com.
(C)1994-2006 M2 COMMUNICATIONS LTD
Yikes, pps doubles in minutes. Good timing of the PR.
eGene Announces Its HDA-GT12(TM) System That Shows Compatibility of Detecting Influenza A Virus, Known as the Avian Flu Virus
IRVINE, Calif., May 04, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of rapid DNA analyzers, announced today that its HDA-GT12(TM) Genetic Analyzer shows compatibility of detecting the influenza A virus, commonly known as the avian flu virus. The automatic analysis process is less than six minutes. The company has demonstrated that its system platform can handle 12 RT-PCR amplified virus samples in six minutes, or at a sample analysis rate of two samples per minute.
As an acute respiratory infection, rapid detection of the influenza A virus is important. "The virus naturally infects humans and other mammalian species such as swine, horse and avian species," said Dr. Ming Liu, acting CEO of the company. "The concerns of a human outbreak of the avian influenza virus have raised significant concerns. Our system can rapidly detect whether we are dealing with an ordinary flu strain or the more serious avian strain. Furthermore, genetic analysis is one of the effective ways to determine whether the virus has mutated to a point where it is dangerous to humans. The need to perform this analysis rapidly cannot be understated in today's world where an airplane ride can transmit a virus thousands of miles in a short period of time."
The HDA-GT12 system uses a consumable multi-channel cartridge that can be used to detect multiple influenza samples simultaneously. The cartridge is engaged to eGene's system and can automatically inject and analyze 12 DNA samples at the same time for results available in six minutes, or for 96 samples from a PCR plate for results available in 50 minutes -- less than an hour.
"This automated and affordable system can be easily operated for avian influenza virus detection," said Dr. Liu.
He noted that eGene recently tested its system utilizing the reagents from In-Vitro Diagnostic FluAVision kits provided by DNA Technology A/S (Denmark). Positive control of influenza A from the testing kit was used for amplification and analyzed with the eGene HDA-GT12 system.
Previously, eGene explained that its analyzer, if placed in airports and other ports of entry throughout the world, can be used to determine if the flu virus is present in the DNA samples of travelers entering -- or leaving -- a given locale.
"The fact that our compact, low-cost, automated digital genetic analysis system platform can do the detection and analysis work in a short time means that should a flu pandemic break out, our system could easily detect and notify officials of a virus carrier who may not be exhibiting physical symptoms of the flu. This is very important, because with illnesses like the flu, the virus is already present and multiplying even in the absence of physical symptoms," explained Dr. Liu. "This could potentially stop the spread of the flu."
eGene currently sells its HDA-GT12 system in more than 100 hospitals and research centers worldwide, and is looking to expand U.S. distribution.
The HDA-GT12(TM) Genetic Analyzer analyzes the genetic fingerprints of living organisms through the microsatellites AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
I believe EGEI is now in buying range. They have the technology and a partnership of some sort will happen. In the meantime, I'm picking up some cheap shares.
Looks like it may hold in the .6 s if we make it through today. Maybe they will have some good news about a distributor next month. glta and have a great weekend
In looking at the patent, it's dated 2000.
It may not be one of their top projects now.
Jim
Thanks for posting that. This is the type of patent that the Supreme Court will most likely shoot down as they review patent law infringement cases. They will be questioning patents of ideas that anyone could come up with (eg. what if an airline just decided to do this on their own with no knowledge that this has been thought of and patented?). Personally, I think this is the type of patent that needs to be thrown out. Patents should require technical/chemical/physical creations with clear specifications and are unique. Now, can I go and create a patent stating that DNA be collected for all persons crossing the border?? If I patent that and they independently come up with the idea to do it, is that a patent infringement? It is ridiculous to patent ideas that could come about by a little critical thinking by any normal person. This is where lawyers get rich and companies go broke pursuing patent infringements or defending against them. It's getting out of hand.
The company needs to stick with their Analyzers and spend time marketing them. Maybe the next PR they issue will say that "Egene Inc. is seeking buyers in the USA".
Sorry for ranting but it hit a nerve. The Analyzer is why I am in this one but the company is either "unfocused" as a previous poster mentioned and/or need to hire someone who can assert this product into the marketplace.
Here's the patent for their idea....no mention of hardware, software....just storage of DNA. Idea may be enough but surprised me that the testing wasn't included.
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fn...
just a note for you guys.
I was a holder in egei and I solt at 1.80
I want back in but I've got no bp left.
But you might get a jump as a new movie about the bird flu is coming out. It may have an impact on egei since it may frighten people. It may propel the idea of airports all the more tempting...
just a thought.
Aug
It would make more sense to check for the bird flue or other serious communicable diseases.
If the price was right, it would make more sense developing a test for mad cow disease.
So far their approach seems a little unfocused.
Jim
They've been looking for a USA distributor for a while. Haven't heard that they have found one. Now they're looking for a partner in this Airport venture. Hope they have better luck.
If you were on the plane that crashed (they check IDs 2 or more times before you get to the plane), why would anyone feel they need a DNA sample left with the airline? Just like life insurance salesmen, they can probably talk enough people into the need to do this through some type of fear mechanism. So, maybe it has potential but I just don't get it and I won't be leaving my DNA anywhere. What are people going to do, spit in a cup and write our names on the side to leave it at the airline terminal for later ID? (tongue in cheek of course). What does this have to do with their machines? Sorry, this idea doesn't thrill me a heck of a lot. In fact, it almost scares me that this is the best idea they could come up with. Hope that I eat crow and this turns out good but until then ... just waiting for some sales info for their analyzers. Let's find a USA distributor. That's the meal ticket IMO
Press Release Source: eGene Inc.
eGene is Seeking Partners for Its Business of DNA Samples Collection in Airport Terminals
Thursday April 27, 12:40 pm ET
IRVINE, Calif.--(BUSINESS WIRE)--April 27, 2006--eGene Inc. (OTCBB:EGEI - News), a leading biotechnology company, announced that it is looking for global business partners in the DNA sample collection in airport terminals.
ADVERTISEMENT
The company's leading product, the compact and automated digital genetic analyzer, HDA-GT12(TM), is already achieving rapid penetration and acceptance in the current genetic research and testing market. Acting CEO of eGene, Dr. Ming Liu, said, "The DNA samples collection combines both the informative and instrumental aspects of DNA analysis, which is an integral part of our business approach."
eGene was awarded a U.S. patent (6,645,718) titled, "DNA sample collection for identification." The patent describes a process of collecting DNA samples for identification purposes in the event of a cataclysmic accident. This is a new, low-cost way to benefit air travel passengers and their families.
For example, in the last decade, hundreds of plane crash victims have remained unidentified because of incomplete information. Dr. Liu believes that airline passengers can take advantage of the company's patented identification technology and process in combination with flight insurance purchases, or through the requirements of various airlines.
"Passengers can choose to temporarily store their DNA samples at an airport terminal for specific flights," Dr. Liu explained. "In the event of an accident, the stored samples can be sent to authorized DNA testing labs for faster personal identification. This benefits the victims' families, the airlines and the insurance companies by avoiding time-consuming and costly individual DNA identification work."
The company is looking for a partner to collaborate with on this venture, which it emphasizes has tremendous business potential. "Even if only 10 percent of all travelers chose to use this service, we would be collecting millions of samples daily," Dr. Liu said. "We are eagerly positioning our company to catch the wave of genetic-related business."
Interested parties can contact the company for further information.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
Contact:
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
--------------------------------------------------------------------------------
Source: eGene Inc.
eGene is Seeking Partners for Its Business of DNA Samples Collection in Airport Terminals
IRVINE, Calif., Apr 27, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading biotechnology company, announced that it is looking for global business partners in the DNA sample collection in airport terminals.
The company's leading product, the compact and automated digital genetic analyzer, HDA-GT12(TM), is already achieving rapid penetration and acceptance in the current genetic research and testing market. Acting CEO of eGene, Dr. Ming Liu, said, "The DNA samples collection combines both the informative and instrumental aspects of DNA analysis, which is an integral part of our business approach."
eGene was awarded a U.S. patent (6,645,718) titled, "DNA sample collection for identification." The patent describes a process of collecting DNA samples for identification purposes in the event of a cataclysmic accident. This is a new, low-cost way to benefit air travel passengers and their families.
For example, in the last decade, hundreds of plane crash victims have remained unidentified because of incomplete information. Dr. Liu believes that airline passengers can take advantage of the company's patented identification technology and process in combination with flight insurance purchases, or through the requirements of various airlines.
"Passengers can choose to temporarily store their DNA samples at an airport terminal for specific flights," Dr. Liu explained. "In the event of an accident, the stored samples can be sent to authorized DNA testing labs for faster personal identification. This benefits the victims' families, the airlines and the insurance companies by avoiding time-consuming and costly individual DNA identification work."
The company is looking for a partner to collaborate with on this venture, which it emphasizes has tremendous business potential. "Even if only 10 percent of all travelers chose to use this service, we would be collecting millions of samples daily," Dr. Liu said. "We are eagerly positioning our company to catch the wave of genetic-related business."
Interested parties can contact the company for further information.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
eGene's DNA Analyzer Used for Anti-Tumor Medication-Related Large-Scale Population Genotyping; Report Indicates Analyzer is a Highly Efficient Technique in a Clinical Laboratory Setting for Genotyping Related to Anti-Tumor Medication
IRVINE, Calif., Apr 25, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that its analyzer was used in large-scale screening for genotyping related to anti-tumor medication and was found to be a highly efficient tool in a clinical laboratory setting. The research report will be published in the coming issue of Analytical Biochemistry 352 (2006) 148-150.
Dr. Ming S. Liu, acting CEO of eGene, noted: "A recent study has demonstrated that the determination of a certain individual genotype will be essential to future anti-tumor medication. The genotype of an enzyme (deoxycytidine Kinase) in our body may represent a significant influence on the efficacy for acute myeloid leukemia treatment. The result of genotyping will not only provide information for patient treatment, but also indicate the direction of future cancer drug development.
"The best way for future medication would be to identify the individual genotype of certain genes and treat the disease with the right medicine," he continued. "Our HDA-GT12 genetic analyzer could play a major role in genotyping analysis. It is a compact, low-cost, automated digital genotyping system, which will be useful in hospitals, outpatient facilities, clinical laboratories and the pharmaceutical industry for medication-related genotyping analysis."
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
or
Andrew Ponzo, 312-943-1100, ext. 17
aponzo@janispr.com
Copyright Business Wire 2006
It's strange with this stock, when the price plummets like this usually the company is raising funds from stock shares.
Oh well, Jim
American Bulls is a candle formation prediction...and that's about it. I use it only when other indications are jelling. Just trying to kick up the stocks heels alittle. Until there's volume it's a floundering ship. I got a core holding...averaging about $1.10.
BUT I did get some IESV that's into methanol and about to get into ethanol. Been a good flipper for me for several years and now I'm gonna load up on it, slowly. Supposed to kick off pipeline grade methanol by July 06.
fox from what i'm seeing egei broke through support and now has resistance at .88. next support is at .42. news of bird flu or about a contract for egei, as we know, could send this thing flying, but i'm waiting for a better oversold confirmation before i load the boat. i think it needs to land hard and maybe even retest that level before we know a bottom is in. lots of this is driven by fundamentals, unfortunately, b/c the market is pricing in to the stock minimal earnings, plus low visibility, and infrequent PRs.
american bulls may not account for stocks like egei that are so incredibly news driven. also an extremely low float can increase downside as well as upside. does their model take this into account?
right now oil prices are so high, and tensions with iran are all anyone is really thinking about. it's interesting how bird flu, even when there's news, seems like less of an immediate danger to investors right now. all the bf stocks seem to have sold off in favor of ethanol!
Could be the turnaround ->
http://www.americanbulls.com/StockPage.asp?CompanyTicker=EGEI&MarketTicker=OTC&TYP=S
thanks a lot, rags! good luck!
brikk, don't know what you mean by "up to the minute" but if you have a free account on Yahoo, create a stock portfolio, and stick egei.ob in your portfolio, news releases show up pretty quickly after their release there. I put all my stocks there and just check the bottom of the page throughout the day to see if any of them have news for the day.
Just found this board so I am glad to see someone is talking about this company. I have owned it for a few weeks.
rags
Thought you might enjoy the reply:
Dear Jim,
Thanks for your interest in eGene. Please see our response in blue.
Regards,
Varouj Amirkhanian
Executive VP / Director
Instrument Systems R&D
eGene, Inc.
17841 Fitch
Irvine, CA 92614
Ph: (949) 250-8686
Fax: (949) 250-8833
www.egeneinc.com
The hardest part of being a investor in your company is understanding the 100 machines you currently have out there and are they being actively used. It would also be helpful to understand the economy of what you're offering and do you see the jell packs as a good future revenue stream?
Yes, we have shipped more than 120 units worldwide. They are being used by our assigned distributors as demo units and more than 100 units have been installed at customer labs ranging in University Research labs, Pharmaceutical Companies, Food Industry, Law Enforcement, CDC, large Government Organizations and small businesses all involved in DNA/RNA type analysis/applications.
Here are some of the Users:
· Research Institutes:
§ Riken Genomic Sciences Center, National Institute of Health Sciences, National Institute of Technology and Evaluation, Research Institute for Natural Science, National Institute of Genetics, National Agricultural Research Center, Central Laboratories for Experimental Animals, National Institute for Basic Biology, National Institute of Livestock and Grassland Science (Japan);
§ International Vaccine Institute, Forest Research Institute, National Institute of Crop Science (Korea);
§ Academic Sinica, Agriculture Research Institute, Center for Disease Control (Taiwan);
§ Research Institute of Molecular Pathology (Austria) ;
§ Australian Genome Research Facility (Australia);
· Universities:
§ Tokyo University, Osaka University, Kyoto University, Teikyo University, Hirosaki University, Nagoya University (Japan);
§ Lausanne University (Switzerland),
§ Padua University (Italy);
§ Univ.Calif Irvine; Ohio State University (USA);
§ Univ.Innsbruck (Austria)
· Hospital & Medical Schools:
§ Univ.Mass. Medical Center, Boston Children Hospital (USA),
§ Saitam Cancer Center, Jichi Medical School (Japan),
§ National Taiwan University Hospital, Taiwan Mackay Memorial Hospital, Taiwan Cathay General Hospital, National Young Ming Medical School (Taiwan)
· Pharmaceutical/ Biotech Industry:
§ Glaxosmithkline, Johnson & Johnson, GeneVault, Texas BioGene, Transgenomic, Inc. Invitrogene, Inc. (USA),
§ Hitachi Science Systems, Ltd, Dainippon Pharmaceutical Co., LTD. Nippon Paper Group, Takii Seed Company (Japan)
§ Johnson & Johnson (Belgium & US)
I hope you don't mind a novice question, can your equipment be used to test for Mad Cow disease and would it be economically feasible?
Yes, our technology is CE (Capillary Electrophoresis, please check our web site for more: www.egeneinc.com) with fluorescence detection. And by altering the gel chemistry for the disposable cartridges one can use it for Mad Cow disease detection as well.
If a specialty medical clinic was created, could a single test be used to cover several different diseases, like Alzheimer, Multiple scleroses ect, would this be a computer program looking for different markers?
Yes, We would use different Gel-Cartridges with specific Markers to cover the range of tests.
Is your biggest problem now the political ramifications of letting so many lab tech's go, when your product removes most of their usefulness?
No, the Instrument does not remove people, it improves productivity and efficiency of the testing labs by automating the high-throughput DNA/RNA screening process, which translates to lowers cost per sample. The automated analyzer allows the high skilled technicians (mostly Ph.D.s) to spend their valuable time in more productive manner, to do better planning of their experiments/tests.
I thought I would send the company a question or two and see if they would answer.
It occurred to me that if they could test for Mad Cow disease, a mobile lab going from farm to farm could create a great revenue stream.
This could also be used for other applications.
Jim
The question I have is they say there are 100 machines currently out there, where are they?
I believe that this claim is true and also if we new were they are we would look at this company much more fondly.
JMHO, Jim
If they get human to human strains this stock will pop just thru concept and a SO of 17 mil...but for long term you're right.
There is lots of fluff in their news releases.They need to get contracts and post $$$$$ results. I was told they only have around 12 employees and I think that number is high. Be careful with this one and call company for facts.
OT...Your over at AURC too. Kinda the same situation there. I don't have much there but I read the board daily. Alot of millionaires will be created in that one.
I like your stock pics. Watch EGEI go.
Also, I love these boards before the bashers get on board...large rise in the PPS will bring em like roaches.
I do get excited when a stock's about to pop. GNBT and XSNX are the two latest that have overflowed my cup. Buckle up.
i've got a good sized stack myself. sold some dogs over the last week and loaded up.
ANY DAY NOW, RIGHT???
i must admit, i don't normally get this excited about a stock, and i think we're all in on the ground floor with this one.
If the stockholders here are like me their just not gonna give up their shares. I think there's a tight hold on a tiny float...that's why we see it go up 20% in one trade. Sideliners are waiting for weaker hands to fold. This is the kinda stock that leaves sideliners and weaker hands behind in an instant. I'm getting all I can. But if it takes off now I'm set.
if we get the right kind of PR even centenarians will get all hot and bothered! LOL
but, yeah, i agree with you. the sky really is the limit. it's just a matter of EGEI partnering with the right companies that already have visibility and want to add their marketing muscle to EGEI's genius technology.
i could see a medtronic picking them up, too. total buy-out. the price would peg and we'd be sitting pretty. but i'd much rather see the company grow and do it in their own way as buyouts have a tendency to limit shareholder's gains.
btw, thanks to all who have been posting the new PRs as they come. i've yet to work out a way of getting up to the minute PR release info on EGEI, and, with the way it tends to trade on news, this is cause for some concern!
good luck all.
You know that in all their PR's they state that there are 100 of their machines sprinkled around.
They also sell supplies for these machines, who would have guessed that they could be used on rice?
It sounds to me like we have a machine that could be crossed marketed to several industries, and the skies the limit.
I have been known to get over excited, not bad for 55... LOL
Jim
thanks for the news post. IMHO this is just one more reason why EGEI should be on everyone's list, yet the stock is going nowhere. very frustrating. i think all we need is one big PR about a major contract and we'll be vaulted to a whole new level of visibilty. i'm still holding strong.
eGene's DNA Analyzer Used for Rice Mutation Screening; Application Has Implications for Use in Plant Research and Food Supply Worldwide
IRVINE, Calif., Apr 12, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, today announced that its analyzer was used recently by the Japan National Institute of Genetics for large-scale rice mutation screening.
The results of this screening were published in a Japanese Rice Genetics Newsletter, Vol. 22, and the text of that paper can be found at http://www.shigen.nig.ac.jp/rice/rgn/vol22/v26.html.
Dr. Ming S. Liu, acting CEO of eGene, noted: "This is an application for our technology that could have tremendous importance in the field of agriculture. Our system can be used in modified TILLING (Targeting Induced Local Lesion in Genome) method to screen SNP (single nucleotide polymorphism) for large-scale rice mutation screening, and it only took an eight-minute electrophoresis process to get the result." He continued: "Plant genetic research is a large field in many countries. Our automated system can be an effective tool for plant researchers to screen complicated plant genetic mutation. eGene's HDA-GT12 Genetic Analyzer has experienced very quick acceptance from the agriculture research community."
Dr. Liu explained that TILLING is a genetic tool that makes it possible to develop seeds that have genetic mutations that can benefit consumers. "For example, it might be possible to either remove a gene or change a gene that causes allergies in individuals. TILLING allows agriculture experts and planters to determine a gene's function, remove undesirable traits or create desirable ones."
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
or
Andrew Ponzo, 312-943-1100, ext. 17
aponzo@janispr.com
Copyright Business Wire 2006
Well the MM's seem to have failed with EGEI, only 4,539 shares traded today and that's not much.
The market has been open for 3 hours for gosh sakes... LOL
Jim
CLARIFICATION of eGene Inc. Press Release
Business Wire - April 11, 2006 18:42
IRVINE, Calif., Apr 11, 2006 (BUSINESS WIRE) -- eGene Inc. (OTCBB:EGEI) wishes to issue the following clarification to its release, BW6060, (CA-EGENE) "eGene Inc. Reports More Than 50% Revenue Growth with Optimistic 2006 Outlook" issued Monday, April 3, 2006:
eGene Inc. (OTCBB:EGEI) today clarified language in its recent press release of April 3, 2006. Ming S. Liu, acting CEO of eGene, said that the phrase "termination agreement with the company's former CEO" should have read "settlement agreement."
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
or
Andrew Ponzo, 312-943-1100, ext. 17
aponzo@janispr.com
Copyright Business Wire 2006
I think it's poised as a "must have" if the flu is found in person to person virus mutation as the detection will be top prioity. Along with the reputable vaccine suppliers it will be on top.
not sure about that. consider farmers pay pennies for their birds. i doubt it would be that cost effective. one of the things making me bullish on this stock is that bird flu aside it's still got so many applications.
There is another item I was thinking about, can this be used for animal testing?
It seems like such a waist killing millions of birds if they are not infected with the bird flue.
Of course cost would play a giant part in if this feasible.
Mad cow disease would be another one.
Jim
i think one factor holding the stock back at the moment is that this tool is ahead of the science in terms of the role genetic mapping currently plays at the dr's office.
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
135
|
Created
|
03/23/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |